Phase 1 trial: LY4052031, another promising nectin-4 targeted therapy

[Maxone73]

Now it's the moment for nectin-4 based ADCs!

LY4052031 is an investigational antibody-drug conjugate (ADC) targeting Nectin-4, a protein overexpressed in cancers like prostate, bladder, breast, non-small cell lung cancer, and gastric cancers. Nectin-4’s low expression in normal tissues makes it an ideal target for precision therapies.

The drug combines a fully human monoclonal antibody with a novel topoisomerase I inhibitor payload, which may reduce resistance and alter toxicity compared to existing ADCs.

Preclinical studies show that LY4052031 binds specifically to Nectin-4-expressing cells, demonstrates potent cytotoxicity, and inhibits tumor growth in xenograft models. Currently in Phase 1 trials, researchers are optimizing its dose, safety, and efficacy across multiple tumor types. If successful, LY4052031 could provide a new, highly selective treatment option for patients with advanced Nectin-4-positive cancers.

prostatewarriors.com/2025/0...

EDIT: they are actually 2 different ADC, LY4052031 and LY4101174

[Maxone73]

EDIT: they are actually 2 different ADC, LY4052031 and LY4101174